Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-02-15
1998-10-20
Low, Christopher S. F.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
424 937, 424 9321, 514 2, 800 2, 435352, 435353, 435354, 435366, 4353201, 4351723, A01N 4304
Patent
active
058246550
ABSTRACT:
The present invention provides methods for reducing a pathology in a subject characterized by a deleterious accumulation of TGF-.beta.-induced extracellular matrix in a tissue by introducing a nucleic acid encoding a TGF.beta.-specific inhibitory agent or active fragment thereof into a cell in the subject. In one embodiment, the nucleic acid encoding the TGF-.beta. specific inhibitory agent is introduced into a cell in vivo by injection, for example, in skeletal muscle. In another embodiment, the nucleic acid encoding the TGF-.beta. specific inhibitory agent is transfected into a cell ex vivo to obtain a cell expressing the agent, and the cell is then administered into the subject to be treated. TGF-.beta. specific inhibitory agents of the present invention include, but are not limited to, members of the decoring family of proteoglycans such as decorin, biglycan, fibromodulin and lumican or an antibody specific for TGF-.beta.. Pathologies that can be reduced by the present invention include various fibrotic diseases and conditions.
REFERENCES:
Yamaguchi et al, Nature, vol. 336, pp. 244-246 17 Nov. 1988.
Gutierrez et al, The Lancet, vol 339: Mar. 21, 1992, pp. 715-721.
Friedmann, Cancer (Supp), Sep. 1992, vol. 70(6) pp. 1810-1818.
Marshall, Science, 269:1050-1055, 1995.
Miller et al., FASEB J. 9:190-199, 1995.
Culver et al., TIG 10(5):174-178, 1994.
Hodgson, Exp Opin. Ther. Pat., 5(5):459-469, 1995.
NIH, "Report and Recommendations", Dec. 7, 1995, 1-40.
Yamamoto et al., May 22, 1987, "Quantitative and qualitative studies of antibody-induced mesangial cell damage in the rat," Kidney International 32:514-525.
Bagchus, et al., 1986, "Glomerulonephritis Induced by Monoclonal Anti-Thy 1.1 Antibodies," Laboratory Investigation55:680-687.
Border, 1988, "Distinguishing minimal-change disease from mesangial disorders," Kidney International 34:419-434.
Isaka et al., 3, Sep. 1995, "Decorin Gene Therapy for Experimental Glomerulonephritis," J. Am. Soc. Nephrol 6:897.
Fitzpatrick et al., 1994, "Transforming Growth Factor-Beta: Antisense RNA-Mediated Inhibition Affects Anchorage-Independent Growth, Tumorigenicity and Tumor-Infiltrating T-Cells in Malignant Mesothelioma," Growth Factors 11:29-44.
Wolfe, Jon A. et al., "Direct Gene Transfer into Mouse Muscle in Vivo." Science 247:1465-1468 (1990).
Kaneda, Yasufumi et al., "Increased Expression of DNA Cointroduced with Nuclear Protein in Adult Rat Liver." Science 243:375-378 (1989).
Kato, Keiko et al., "Expression of Hepatitis B Virus Surface Antigen in Adult Rat Liver." J. Biol. Chem. 266:3361-3364 (1991).
Nakanishi, Mahito et al., "Efficient Introduction of Contents of Liposomes into Cells Using HVJ (Sendai Virus)." Exp. Cell Res. 159:399-409 (1985).
Yamaguchi, Yu et al., "Negative Regulation of Transforming Growth Factor-.beta. by the Proteoglycan Decorin." Nature 346:281-284 (1990).
Border, Wayne A. et al., "Natural Inhibitor of Transforming Growth Factor-.beta. Protects Against Scarring in Experimental Kidney Disease." Nature 360:361-364 (1992).
Border, Wayne A. et al., "Suppression of Experimental Glomerulonephritis by Antiserum Against Transforming Growth Factor .beta.1." Nature 346:371-374 (1990).
Morishita, Ryuichi et al., "Intimal Hyperplasia After Vascular Injury is Inhibited by Antisense cdk 2 Kinase Oligonucleotides." J. Clin. Invest. 93:1458-1464 (1994).
Kahari, Veli-Matti et al., "Differential Regulation of Extracellular Matrix Proteoglycan (PG) Gene Expression." J. Biol. Chem. 266:10608-10615 (1991).
Takeshita, Satoshi et al., "Increased Gene Expression after Liposome-Mediated Arterial Gene Transfer Associated with Intimal Smooth Muscle Cell Proliferation." J. Clin. Invest. 93:652-661 (1994).
Okuda, Seiya et al., "Elevated Expression of Transforming Growth Factor-.beta. and Proteoglycan Production in Experimental Glomerulonephritis." J. Clin. Invest. 86:453-462 (1990).
Border, Wayne A. and Ruoslahti, Erkki "Transforming Growth Factor-.beta. in Disease: The Dark Side of Tissue Repair," J. Clin. Invest. 90:1-7 (1992).
Isaka, Yoshitaka et al., "Glomerulosclerosis Induced by In Vivo Transfection of Transforming Growth Factor-.beta. of Platelet-derived Growth Factor Gene into the Rat Kidney." J. Clin. Invest. 92:2597-2601 (1993).
Westergren-Thorsson, Gunilla et al., "Altered Expression of Small Proteoglycans, Collagen, and Transforming Growth Factor-.beta..sub.1 in Developing Bleomycin-induced Pulmonary Fibrosis in Rats." J. Clin. Invest. 92:632-637 (1993).
Yamamoto, Tatsuo et al., "Sustained Expression of TGF-.beta.1 Underlies Development of Progressive Kidney Fibrosis." Kidney Int. 45:916-927 (1994).
Border, Wayne A. and Noble, Nancy A., "Transforming Growth Factor .beta. in Tissue Fibrosis." New England J. of Med. 331:1286-1292 (1994).
Takeuchi, Yasuhiro et al., "Bone Matrix Decorin Binds Transforming Growth Factor-.beta. and Enhances Its Bioactivity." J. Biol. Chem. 269:32634-32638 (1994).
Funderburgh et al., "Sequence and Structural Implications of a Bovine Corneal Keratin Sulfate Proteoglycan Core Protein: Protein 37B Represents Bovine Lumicon and Proteins 37 A aaand 25 Are Unique." J. Biol. Chem. 268:11874-11880 (1993).
Takahashi et al., "Keratin Sulfate and Dermatin Sulfate Proteoglycans Associate with Type VI Collagen in Fetal Rabbit Cornea." J. Histochem. Cytochem. 41:1447-1457 (1993).
Blochberger et al., "Isolation and Partial Characterization of Lumicon and Decorin From Adult Chicken Cornea." J. Biol. Chem. 267:20613-20619 (1992).
Niwa, et al., "Efficient Selection for High-Expression Transfectants with a Novel Eukaryotic Vector." Gene 108:193-199 (1991).
Antonsson et al., "Structure and Deduced Amino Acid Sequence of the Human Fibromodulin Gene." Biochem. Biophys. Acta. 1174:204-206 (1993).
Fisher et al., "Deduced Protein Sequence of Bone Small Proteoglycan I (biglycan) shows Homology with Proteoglycan II (Decorin) and Serveral Nonconnective Tissue Proteins in a Variety of Species." J. Biol. Chem. 264:4571-4575 (1989).
Fukushima et al., "Localization of Transforming Growth Factor Beta Binding Site in Betaglycan. Comparison With Small Extracellular Matrix Proteins." J. Biol. Chem. 268:22710-22715 (1993).
Lopez-Casillas et al., "Structure and Expression of the Membrane Proteoglycan Betaglycan, a Component of the TGF-.beta. Receptor System." Cell 67:785-795 (1991).
St-Jacques et al., Molecular Characterization and in Situ Localization of Murine Endoglin Reveal that it is a Transforming Growth Factor-Beta Binding Protein of Endothelial and Stromal Cells. Endocrinology 134:2645-2657 (1994).
Krusius and Ruoslahti, "Primary Structure of an Extracellular Matrix Proteoglycan Core Protein Deduced from Cloned cDNA." Pro. Natl. Acad. Sci. USA 83:7683-7687 (1986).
Low Christopher S. F.
The University of Utah
LandOfFree
Anti-transforming growth factor-.beta. gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-transforming growth factor-.beta. gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-transforming growth factor-.beta. gene therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-244386